# Drug Price Transparency Act of 2023

This bill requires pharmaceutical companies to publicly disclose the prices they charge for prescription drugs and how those prices are set. Right now, drug pricing is largely kept secret—companies negotiate different prices with different insurance companies and pharmacy benefit managers, and these negotiations happen behind closed doors. This bill would pull back that curtain and make pricing information available to the public, Congress, and government agencies.

The main goal is to give patients, doctors, and policymakers a clearer picture of what drugs actually cost and why prices are what they are. When you go to a pharmacy, you might pay $50 for a medication while your neighbor pays $200 for the exact same drug, depending on their insurance. This bill aims to shed light on those hidden price differences. By making this information transparent, supporters believe it could help reduce drug prices overall, since companies would face public scrutiny if their prices seem unreasonably high compared to other countries or to what they charge elsewhere.

The bill would affect pharmaceutical companies most directly, requiring them to report pricing data. It could also impact insurance companies and pharmacy benefit managers who negotiate drug prices on behalf of patients. For everyday people, the practical benefit would be greater visibility into why drugs cost what they do, which could fuel public pressure for lower prices and potentially help patients understand their medication costs better. However, the bill doesn't directly cap prices or guarantee lower costs—it's primarily about transparency, with the idea that sunlight is the best disinfectant when it comes to pricing practices.

Drug Price Transparency Act of 2023

Braun, Mike

Drug Price Transparency Act of 2023 This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.